- $22.91bn
- $21.96bn
- $1.18bn
Annual income statement for Symbotic, fiscal year end - September 30th, USD millions except per share, conversion factor applied.
2019 September 28th | 2020 September 26th | 2021 September 25th | 2022 September 24th | 2023 September 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 100 | 92.1 | 252 | 593 | 1,177 |
| Cost of Revenue | |||||
| Gross Profit | -20 | -18.9 | 10.4 | 99.6 | 190 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 206 | 202 | 374 | 734 | 1,400 |
| Operating Profit | -106 | -110 | -122 | -140 | -223 |
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -104 | -110 | -122 | -139 | -213 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -104 | -110 | -122 | -139 | -208 |
| Minority Interest | |||||
| Equity in Affiliates | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -104 | -110 | -122 | -6.86 | -23.9 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -130 | -139 | -155 | -6.86 | -23.9 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -2.39 | -2.56 | -2.86 | -0.127 | 0.032 |
| Dividends per Share |